250 related articles for article (PubMed ID: 30746719)
1. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.
Pfeiffenberger J; Lohse CM; Gotthardt D; Rupp C; Weiler M; Teufel U; Weiss KH; Gauss A
J Inherit Metab Dis; 2019 Mar; 42(2):371-380. PubMed ID: 30746719
[TBL] [Abstract][Full Text] [Related]
2. Serum 'free' copper in Wilson disease.
Walshe JM
QJM; 2012 May; 105(5):419-23. PubMed ID: 22139498
[TBL] [Abstract][Full Text] [Related]
3. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
Merle U; Schaefer M; Ferenci P; Stremmel W
Gut; 2007 Jan; 56(1):115-20. PubMed ID: 16709660
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism.
Shimizu N; Fujiwara J; Ohnishi S; Sato M; Kodama H; Kohsaka T; Inui A; Fujisawa T; Tamai H; Ida S; Itoh S; Ito M; Horiike N; Harada M; Yoshino M; Aoki T
Transl Res; 2010 Dec; 156(6):350-7. PubMed ID: 21078496
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of Wilson disease].
Smolarek C; Stremmel W
Z Gastroenterol; 1999 Apr; 37(4):293-300. PubMed ID: 10378366
[TBL] [Abstract][Full Text] [Related]
6. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML; Czlonkowska A; Zuin M; Cassiman D; Twardowschy C; Poujois A; Gondim FAA; Denk G; Cury RG; Ott P; Moore J; Ala A; D'Inca R; Couchonnal-Bedoya E; D'Hollander K; Dubois N; Kamlin COF; Weiss KH;
Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1092-1102. PubMed ID: 36183738
[TBL] [Abstract][Full Text] [Related]
7. Wilson's disease: assessment of D-penicillamine treatment.
Van Caillie-Bertrand M; Degenhart HJ; Luijendijk I; Bouquet J; Sinaasappel M
Arch Dis Child; 1985 Jul; 60(7):652-5. PubMed ID: 4026361
[TBL] [Abstract][Full Text] [Related]
8. Zinc Therapy for Wilson Disease in Children in French Pediatric Centers.
Santiago R; Gottrand F; Debray D; Bridoux L; Lachaux A; Morali A; Lapeyre D; Lamireau T
J Pediatr Gastroenterol Nutr; 2015 Dec; 61(6):613-8. PubMed ID: 26230903
[TBL] [Abstract][Full Text] [Related]
9. Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.
Seessle J; Gotthardt DN; Schäfer M; Gohdes A; Pfeiffenberger J; Ferenci P; Stremmel W; Weiss KH
J Inherit Metab Dis; 2016 Jan; 39(1):125-30. PubMed ID: 26067812
[TBL] [Abstract][Full Text] [Related]
10. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
Walshe JM
QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
[TBL] [Abstract][Full Text] [Related]
11. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
[TBL] [Abstract][Full Text] [Related]
12. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
Siegemund R; Lössner J; Günther K; Kühn HJ; Bachmann H
Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
[TBL] [Abstract][Full Text] [Related]
15. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
16. Oral zinc sulphate for Wilson's disease.
Van Caillie-Bertrand M; Degenhart HJ; Visser HK; Sinaasappel M; Bouquet J
Arch Dis Child; 1985 Jul; 60(7):656-9. PubMed ID: 4026362
[TBL] [Abstract][Full Text] [Related]
17. Switching Pharmacological Treatment in Wilson Disease: Case Report and Recommendations.
Leung M; Wu Lanzafame J; Medici V
J Investig Med High Impact Case Rep; 2020; 8():2324709619896876. PubMed ID: 31920114
[No Abstract] [Full Text] [Related]
18. Urinary copper excretion before and after oral intake of d-penicillamine in parents of patients with Wilson's disease.
Vieira J; Oliveira PV; Juliano Y; Warde KR; Deguti MM; Barbosa ER; Carrilho FJ; Cancado EL
Dig Liver Dis; 2012 Apr; 44(4):323-7. PubMed ID: 22169274
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment of Wilson disease in Japan].
Shimizu N
Rinsho Shinkeigaku; 2019 Sep; 59(9):565-569. PubMed ID: 31474637
[TBL] [Abstract][Full Text] [Related]
20. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment.
Arnon R; Calderon JF; Schilsky M; Emre S; Shneider BL
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):596-602. PubMed ID: 17460493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
